Literature DB >> 23274167

Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping.

Carol Beadling1, Tanaya L Neff, Michael C Heinrich, Katherine Rhodes, Michael Thornton, John Leamon, Mark Andersen, Christopher L Corless.   

Abstract

There is growing demand for routine identification of actionable mutations in clinical cancer specimens. Genotyping platforms must provide rapid turnaround times and work effectively with limited amounts of formalin-fixed, paraffin-embedded (FFPE) tissue specimens that often yield poor quality DNA. We describe semiconductor-based sequencing of DNA from FFPE specimens using a single-tube, multiplexed panel of 190 amplicons targeting 46 cancer genes. With just 10 ng of input DNA, average read depths of 2000× can be obtained in 48 hours, with >95% of the reads on target. A validation set of 45 FFPE tumor specimens containing 53 point mutations previously identified with a mass spectrometry-based genotyping platform, along with 19 indels ranging from 4 to 63 bp, was used to evaluate assay performance. With a mutant allele ratio cutoff of 8%, we were able to achieve 100% sensitivity (95% CI = 97.3% to 100.0%) and 95.1% specificity (95% CI = 91.8% to 98.0%) of point mutation detection. All indels were visible by manual inspection of aligned reads; 6/9 indels ≤12 bp long were detected by the variant caller software either exactly or as mismatched nucleotides within the indel region. The rapid turnaround time and low input DNA requirements make the multiplex PCR and semiconductor-based sequencing approach a viable option for mutation detection in a clinical laboratory.
Copyright © 2013 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23274167     DOI: 10.1016/j.jmoldx.2012.09.003

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  65 in total

Review 1.  Advances in the Molecular Analysis of Soft Tissue Tumors and Clinical Implications.

Authors:  Adrian Marino-Enriquez
Journal:  Surg Pathol Clin       Date:  2015-09

2.  Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data.

Authors:  Catherine Grasso; Timothy Butler; Katherine Rhodes; Michael Quist; Tanaya L Neff; Stephen Moore; Scott A Tomlins; Erica Reinig; Carol Beadling; Mark Andersen; Christopher L Corless
Journal:  J Mol Diagn       Date:  2014-11-07       Impact factor: 5.568

3.  Comparison of custom capture for targeted next-generation DNA sequencing.

Authors:  Eric Samorodnitsky; Jharna Datta; Benjamin M Jewell; Raffi Hagopian; Jharna Miya; Michele R Wing; Senthilkumar Damodaran; Juliana M Lippus; Julie W Reeser; Darshna Bhatt; Cynthia D Timmers; Sameek Roychowdhury
Journal:  J Mol Diagn       Date:  2015-01       Impact factor: 5.568

4.  Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.

Authors:  Diane Tseng; Julie Kim; Andrea Warrick; Dylan Nelson; Marina Pukay; Carol Beadling; Michael Heinrich; Maria Angelica Selim; Christopher L Corless; Kelly Nelson
Journal:  J Am Acad Dermatol       Date:  2014-05-17       Impact factor: 11.527

5.  Association of FGD1 polymorphisms with early-onset breast cancer.

Authors:  Sarah Beasley; Phillip J Buckhaults; Nancy G Pedigo; Christopher L Farrell
Journal:  Oncol Lett       Date:  2016-07-25       Impact factor: 2.967

6.  Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.

Authors:  Christine M Barnett; Michael C Heinrich; Jeong Lim; Dylan Nelson; Carol Beadling; Andrea Warrick; Tanaya Neff; Celestia S Higano; Mark Garzotto; David Qian; Christopher L Corless; George V Thomas; Tomasz M Beer
Journal:  Clin Cancer Res       Date:  2013-12-18       Impact factor: 12.531

Review 7.  Implementing personalized cancer genomics in clinical trials.

Authors:  Richard Simon; Sameek Roychowdhury
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

Review 8.  COLD-PCR Technologies in the Area of Personalized Medicine: Methodology and Applications.

Authors:  Florence Mauger; Alexandre How-Kit; Jörg Tost
Journal:  Mol Diagn Ther       Date:  2017-06       Impact factor: 4.074

9.  Discordant Mutations in Paired Primary and Metastatic Endometrial Adenocarcinomas Identified by Semiconductor-Based Sequencing for Rapid Cancer Genotyping.

Authors:  Colin P Bergstrom; Koen De Geest; Rebecca O'Gara; Christopher L Corless; Terry K Morgan
Journal:  Reprod Sci       Date:  2016-05-11       Impact factor: 3.060

10.  Cancer Driver Log (CanDL): Catalog of Potentially Actionable Cancer Mutations.

Authors:  Senthilkumar Damodaran; Jharna Miya; Esko Kautto; Eliot Zhu; Eric Samorodnitsky; Jharna Datta; Julie W Reeser; Sameek Roychowdhury
Journal:  J Mol Diagn       Date:  2015-09       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.